Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

• Gildeuretinol targets toxic vitamin A dimers that damage retinal cells in Stargardt disease patients, with initial late-stage trial data expected in second half of 2029
• Stargardt disease progressively damages central vision starting in childhood or adolescence, impairing reading, facial recognition, and driving abilities
• The transaction expands Tarsus' eye disease pipeline beyond its approved product Xdemvy for eyelid inflammation and is expected to close in 2026 subject to regulatory approval

Summary: Tarsus to Acquire Alkeus for Up to $800M to Expand Eye Disease Pipeline

Deal Structure:

Tarsus Pharmaceuticals announced the acquisition of privately held Alkeus Pharmaceuticals in a transaction valued at up to $800 million. The deal includes an upfront payment of approximately $450 million—$270 million in cash and $180 million in Tarsus common stock. An additional $350 million in contingent payments is tied to regulatory approval and first commercial sale milestones, plus low-single-digit royalty percentages on net sales.

Key Asset:

The acquisition centers on gildeuretinol (ALK-001), an experimental oral therapy for Stargardt disease, a rare inherited retinal disorder with no approved U.S. treatment. The disease affects over 36,000 clinically diagnosed patients in the United States, typically beginning in childhood or adolescence and progressively damaging central vision, impacting reading, facial recognition, and driving abilities.

Drug Mechanism:

Gildeuretinol targets toxic vitamin A dimer accumulation that damages retinal cells in Stargardt patients, potentially slowing retinal damage and preserving vision.

Timeline:

Initial data from the ongoing late-stage trial is expected in the second half of 2029. The transaction is anticipated to close in 2026, pending regulatory clearance and customary conditions.

Company Background:

Tarsus' existing portfolio includes Xdemvy, approved for demodex blepharitis (eyelid inflammation), and pipeline candidates for eye inflammation and ocular antiseptics.

Market Implications:

This acquisition positions Tarsus to address a significant unmet medical need in rare eye diseases, expanding beyond its current commercial offerings into orphan indications with potentially favorable regulatory pathways and pricing dynamics.